Navigation Links
Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program

ATLANTA--(BUSINESS WIRE)--May 14, 2007--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced the successful completion of the clinical trial program for its new Sular formulation. The study results showed that the new Sular formulation is bioequivalent to Sciele's currently marketed Sular. The new Sular formulation utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.

The data from this study will be combined with the results from the previous clinical trial in the Company's new Sular formulation supplemental New Drug Application (sNDA) filing. As previously announced, the Company confirms its expectation to file an sNDA with the U.S. Food and Drug Administration by end of the second quarter of 2007.

About Sciele Pharma, Inc.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes and Women's Health. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of women and mothers and their babies. Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 800 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has ten approved products in the areas of oral, inhalation and topical delivery. The Company
'"/>




Page: 1 2 3 4

Related medicine technology :

1. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:5/22/2015)... May 20, 2015 Research and Markets( ... "Guide to Prepare Application Dossiers for Oversea ... Edition) " report to their offering. ... of segment market of the most growth potentiality, ... device manufacturers and producers to penetrate such market. ...
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... 22, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... chief executive officer Howie Rosen will be ... officer Tim Morris will be presenting at ... presentations are as follows: Jefferies 2015 Healthcare ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... , July 26 Perrigo Company (Nasdaq: PRGO ... the U.S. Food and Drug Administration to manufacture and market over-the-counter ... fiscal first quarter 2011. Cherry joins the currently available grape flavor ... store brand flavors. , , ...
... July 26 Halt Medical, Inc. announced today ... appointed to its Scientific Advisory Board.  Dr. Rubin will ... develop and implement comprehensive reimbursement strategies.  Dr. Rubin,s distinguished ... medicine, government, and business. Currently, he is Clinical Professor ...
Cached Medicine Technology:Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup 2Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup 3Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor 2
(Date:5/22/2015)... May 22, 2015 Power Systems is proud ... the 2015 race season. Drobeck is in his second year ... a firefighter with the Missoula Fire Department in Missoula, MT. ... Pro in 2014. During his career, he has had 15 ... Drobeck recorded top 10 finishes in all seven of his ...
(Date:5/22/2015)... May 22, 2015 ZH ... IT solutions, announced today that Bill Lane, joins ... the developer of BlueEHS,a first of its kind, ... a customizable Electronic Health Records (EHR) with an ... a telemedicine-enabled comprehensive patient portal, and more. Combined ...
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
(Date:5/22/2015)... A Phase 3 French study, which ... Clinical Oncology (ASCO)’s annual meeting at the end ... patients who received bevacizumab in addition to the ... Genentech, Inc.) is an antibody that blocks angiogenesis ... used to treat many other cancers, including lung ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... that one particularly aggressive type of blood cancer, mixed lineage ... motors running. The cancer cells rely on the normal version ... happens when a piece of chromosome 11 breaks off at ... another chromosome, resulting in a fusion protein that eventually causes ...
... 2, 2010 Researchers at UT Southwestern Medical Center hope ... against drug dependence. Their hypothesis that increasing the normally ... is based on a rodent study demonstrating that blocking new ... addiction and relapse. The study,s findings, available in the ...
... ... releases Meaningful Use Dashboard for Health Systems. The Meaningful Use Dashboard will provide a ... in regards to Meaningful Use Indicators. , ... Columbus, OH (PRWEB) February 26, 2010 -- Health Care ...
... play key role, study finds , FRIDAY, Feb. 26 (HealthDay ... antibodies may contribute to the development of heart disease in ... is an autoimmune illess in which the immune system creates ... that results in damage to tissue and organs, including the ...
... led to 30 percent reduction in lost tissue, study found ... flow of blood to the heart by repeatedly inflating a ... damaged during a heart attack, a new Danish study shows. ... a hospital for treatment of severe heart attacks, the amount ...
... ... a leading medical informatics company, has signed a strategic partnership agreement with Medical ... easy to deploy diagnostic capability across the healthcare enterprise. , , ... Milwaukee (PRWEB) ...
Cached Medicine News:Health News:Cells of aggressive leukemia hijack normal protein to grow 2Health News:Increasing neurogenesis might prevent drug addiction and relapse 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2Health News:New Clues to Lupus' Link With Heart Disease 2Health News:Cutting Off Blood Flow to Heart Limits Damage During Heart Attack 2Health News:Cutting Off Blood Flow to Heart Limits Damage During Heart Attack 3Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 2Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 3
... used to evaluate both low contrast acuity and ... 12.5%) of LogMAR acuity (20/16 to 20/100) are ... the two spatial frequencies of 6 and 12 ... cataract documentation because eye doctors can document cataract ...
... test face is widely used for in or ... presents standard visual acuity from 20/15 to 20/200, ... cycles/degree) and a real-world driver's scene. , ,The ... it provides a standard acuity score, a functional ...
The compact, simple-to-use ECG for medical professionals....
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
Medicine Products: